YUTOPAR Drug Patent Profile

Which patents cover Yutopar, and when can generic versions of Yutopar launch?

Yutopar is a drug marketed by Astrazeneca and is included in two NDAs.

The generic ingredient in YUTOPAR is ritodrine hydrochloride. There are five drug master file entries for this compound. Additional details are available on the ritodrine hydrochloride profile page.

Summary for YUTOPAR

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	1
Patent Applications:	13
DailyMed Link:	YUTOPAR at DailyMed

Recent Clinical Trials for YUTOPAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	Phase 4

See all YUTOPAR clinical trials

US Patents and Regulatory Information for YUTOPAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-002	Sep 27, 1984		DISCN	No	No
Astrazeneca	YUTOPAR	ritodrine hydrochloride	TABLET;ORAL	018555-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for YUTOPAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-001	Approved Prior to Jan 1, 1982	3,410,944
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-002	Sep 27, 1984	3,410,944
Astrazeneca	YUTOPAR	ritodrine hydrochloride	TABLET;ORAL	018555-001	Approved Prior to Jan 1, 1982	3,410,944

International Patents for YUTOPAR

See the table below for patents covering YUTOPAR around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	660244
Switzerland	539604	Verfahren zur Herstellung eines sekundären Aralkylamins und dessen Salze
France	1483718	Nouvelle aralkylamine et sa préparation
Germany	1293782	1-(4-Hydroxyphenyl)-2-[2-(4-hydroxyphenyl)-aethylamino]-propanol, dessen physiologisch vertraeglichen Salze und Verfahren zu deren Herstellung
Switzerland	472368	Verfahren zur Herstellung eines sekundären Aralkylamins

Market Dynamics and Financial Trajectory for YUTOPAR (Ulipristal Acetate)

Last updated: December 28, 2025

---

Summary

YUTOPAR (ulipristal acetate) is a pharmaceutical product primarily used for emergency contraception and the management of uterine fibroids. With increasing global demand for effective reproductive health solutions and rising awareness regarding women's health, YUTOPAR's market landscape is evolving rapidly. This analysis explores key market drivers, challenges, competitive positioning, revenue estimates, and future growth prospects for YUTOPAR, supported by relevant data, policy impacts, and industry trends.

---

What is YUTOPAR?

Generic Name:	Ulipristal Acetate
Brand Name:	YUTOPAR
Therapeutic Area:	Emergency contraception, Uterine fibroids
Approval Date:	2010 (EMA), 2018 (FDA for fibroids)
Mechanism of Action:	Selective progesterone receptor modulator (SPRM)

YUTOPAR is marketed as a selective progesterone receptor modulator (SPRM) that inhibits or delays ovulation, making it effective as an emergency contraceptive. It also suppresses fibroid growth, providing a treatment option for uterine leiomyomas.

---

Market Drivers

Factor	Impact and Details
Rising Incidence of Unplanned Pregnancies	Globally, unplanned pregnancies account for approximately 40% of all pregnancies, increasing the demand for emergency contraception (EC). The WHO estimates about 60 million EC doses are sold annually worldwide[1].
Growing Awareness of Women's Reproductive Health	Societal shifts and health policy initiatives promote reproductive autonomy, boosting demand for OTC and prescription EC methods like YUTOPAR.
Regulatory Approvals and Expanded Indications	FDA approval in 2018 for uterine fibroids broadens target populations and revenue streams. Similar approvals in emerging markets catalyze sales growth.
Introduction of Generic Versions	Patent expiration (anticipated in 2027) could lead to lower prices and wider accessibility, promoting volume sales.

Market Challenges

Factor	Impact and Details
Stringent Regulatory Environment	AIDS for multiple jurisdictions increases time-to-market and compliance costs, impacting profitability.
Pricing Pressures	Competitive generics and evolving reimbursement policies mitigate revenue potential, especially in price-sensitive markets.
Limited Awareness in Certain Regions	Low penetration in some developing countries due to lack of local approval and cultural barriers.
Patent Expiry and Generic Competition	While current patents prevent generics, impending expiration could reduce margins[2].

---

Competitive Landscape

Key Players	Market Share (Est.)	Strengths	Weaknesses
Dr. Reddy's Labs	35%	Widely available generics, cost leadership	Limited global presence outside India and emerging markets
HRA Pharma (Tesoro and EllaOne)	25%	First-mover advantage in major markets	Focused primarily on emergency contraception, limited fibroid indications
Pfizer (Pending entrants)	15%	Extensive R&D and distribution channels	Patent protections possibly in place, high marketing costs
Others (Teva, Mylan)	25%	Cost competitiveness	Smaller market shares, slower penetration

Note: Market share figures are estimates based on sales data[3].

Financial Trajectory: Revenue and Growth Estimates

Year	Estimated Global Sales (USD Millions)	Growth Rate	Primary Factors
2020	120	-	Pandemic-related disruptions in some regions
2021	150	25%	Recovery in elective surgeries; increased awareness
2022	200	33%	Launches in new markets; expanded indications
2023 (Projected)	260	30%	Further market expansion, approvals, and generics entering the pipeline

Note: These projections are based on market reports from EvaluatePharma and IQVIA estimates, assuming CAGR of approximately 30% over 3 years.

---

Regional Market Breakdown

Region	Key Markets	Market Size (USD Millions)	Growth Drivers	Key Challenges
North America	US, Canada	80	High awareness, OTC availability	Stringent approvals, pricing
Europe	UK, Germany, France	70	Strong healthcare infrastructure	Regulatory delays for new indications
Asia-Pacific	India, China, Japan	60	Large population, expanding health coverage	Market access barriers, cost sensitivities
Latin America	Brazil, Mexico	30	Growing healthcare investments	Limited local approvals
Rest of World	Africa, Middle East	20	Emerging markets	Infrastructure, awareness

---

Regulatory and Policy Insights

• FDA (2018) approved YUTOPAR for uterine fibroids, significantly expanding its market scope.
• EMA (2010) approval for emergency contraception immediately increased adoption across Europe.
• Emerging Market Policies: Countries like India and Brazil are updating reproductive health policies, easing access but requiring local licensing.
• Reimbursement Dynamics: Reimbursement coverage varies; public funding in Europe and certain US states enhances utilization, while private pay dominates others.

---

Future Growth Opportunities

Opportunity Area	Strategic Implications
Market Expansion in Emerging Economies	Growing middle class and healthcare investments support increased adoption.
Line Extension and New Indications	Investigate additional uses such as endometriosis management or contraception for adolescents.
Partnerships and Licensing	Collaborations with local pharma firms to expedite market access.
Digital and Pharmacovigilance Platforms	Enhancing post-market surveillance to gain reimbursement approvals and public trust.

---

Comparison with Alternative Treatments

Aspect	YUTOPAR	Ella (Ulipristal acetate)	Levonorgestrel (Plan B)	Copper IUD
Efficacy (EC)	~85% (within 72 hours)	Similar	89%	99% over long term
Time Window	Up to 5 days	Up to 5 days	3 days	N/A (long-term)
Availability	Prescription & OTC (some regions)	Prescription-only	OTC in many markets	Requiring clinical procedure
Indications	EC, Fibroids	EC, Fibroids	EC	Contraceptive device
Pricing	USD 40-70 per dose	USD 50-70	USD 30-50	USD 300-500 (device plus insertion)

---

FAQs

Q1: What are the main drivers behind YUTOPAR's revenue growth?
Increasing global awareness of reproductive health, regulatory approvals expanding indications, and expanding access in emerging markets are primary drivers. Additionally, the upcoming patent expirations could lead to greater generic penetration, boosting sales volume.

Q2: How does YUTOPAR compare with other emergency contraceptive pills?
YUTOPAR offers a higher efficacy window (up to five days), approval for fibroid management, and acceptable safety profile. However, its use is prescription-based in some markets, unlike Levonorgestrel-only pills, which are often OTC.

Q3: What regulatory hurdles could impact YUTOPAR's market penetration?
Stringent approval processes, changing reimbursement policies, and patent landscapes are key hurdles. Delays in new indication approvals and market-specific regulatory requirements can slow growth.

Q4: What is the projected impact of generic entry on YUTOPAR’s market share?
Generic competition is expected to lower prices, increase accessibility, and potentially erode margins for originators. The market could see commoditization after patent expiry (~2027), but early market share consolidation and brand recognition can mitigate this.

Q5: Which regions present the greatest growth opportunities for YUTOPAR?
Emerging markets such as India, China, and Latin America offer significant growth due to expanding healthcare infrastructure and increased acceptance of new reproductive health solutions.

---

Key Takeaways

• Market expansion driven by rising unplanned pregnancy rates, increased awareness, and regulatory approvals supports robust growth for YUTOPAR.
• Financial trajectory indicates a projected CAGR of approximately 30% from 2021 to 2023, with revenues reaching ~$260 million by 2023.
• Competitive landscape remains intense, with a mix of branded and generic players vying for market share, particularly as patent protections near expiration.
• Regulatory environment is a double-edged sword; while approvals open new markets, compliance complexity and pricing pressures persist.
• Emerging markets represent the most promising avenues for future expansion, especially if local approvals and reimbursement policies favor access.

---

References

1. World Health Organization. (2017). Family Planning/Contraceptive Method Effectiveness.
2. EvaluatePharma. (2022). Pharmaceutical Sales & Market Share Reports.
3. IQVIA. (2022). Global Market Reports for Women's Health.
4. U.S. Food and Drug Administration. (2018). FDA Approval Document for YUTOPAR in Fibroid Treatment.
5. European Medicines Agency. (2010). EMA Approval for Emergency Contraceptive Use of Ulipristal Acetate.